Application of Cervista® human papilloma virus high-risk test in cervical cancer screening of Xinjiang Uyghur women

Objective: This study aims to evaluate the diagnostic value of the Cervista^® human papilloma virus (HPV) high-risk (HR) test in cervical cancer and precancerous lesion screening in Xinjiang Uyghur women. Materials and Methods: Three hundred and seventy three Uyghur women from Bachu County underwent the Cervista^® HPV HR test, ThinPrep cytologic test, and cervical biopsy under a colposcope. Then the relationship between the infection rate of high-risk human papilloma virus (HR-HPV), the cytological results, and the histological results was analyzed. Results: With increasing cytological and pathological classification, the HR-HPV infection rate also increased and reached 100% in patients with cervical cancer. The highest proportion of the pathologically positive group consisted of patients with group A9 HPV infection as compared to patients infected with group A5/A6 or A7 HPV. Conclusion: HR-HPV is closely correlated with cervical cancer and precancerous lesions. Group A9 HPV has a high predictive value in cervical disease screening in Uyghur women. When cytological examination shows atypical squamous cells of undetermined significance (ASCUS), the Cervista^® HPV HR test can provide a sensitive differentiation method.

Cervical cancer; Cervista HPV HR test; ThinPrep cytologic test.

[1] Bartholomew D.A., Luff R.D., Quigley N.B., Curtis M., Olson M.C.: “Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples”. J. Clin. Virol., 2011, 51, 38.

[2] Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al.: “Epidemiologic classification of human papilloma virus types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[3] Cheah P.L., Lool L.M.: “P53 immunohistochemical expression: messages in cervical carcinogenesis”. Pathology, 2002, 34, 326.

[4] Sui S., Jiao Z., Niyazi M., S S., Lu P., Qiao Y.L.: “Genotype distribution and behavioral risk factor analysis of human papillomavirus infection in Uyghur women”. Asian Pac. J. Cancer Prev., 2013, 14, 5861.

[5] Kurian E.M., Caporelli M.L., Baker S., Woda B., Cosar E.F., Hutchinson L.: “Cervista HR and HPV 16/18 assays vs hybrid capture 2 assayoutcome comparison in women with negative cervical cytology”. Am. J. Clin. Pathol., 2011, 136, 808.

[6] Quigley N.B., Potter N.T., Chivukula M., Knight M.Z., Welch J.R., Olson M.C.: “Rate of detection of high-risk HPV with two assays in women ≥30 years of age”. J. Clin. Virol., 2012, 52, 23.

[7] Youens K.E., Hosler G.A., Washington P.J., Jenevein E.P., Murphy K.M.: “Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens”. J. Mol. Diagn., 2011, 13, 160.

[8] Munson E., Du Chateau B.K., Nelson B.E., Griep J., Czarnecka J., Amrhein R.D., et al.: “Effect of glacial acetic acid treatment of liquidbased cytology collections on performance of Cervista HPV HR for detection of high-risk human papillomavirus”. J. Clin. Microbiol., 2012, 50, 2129.

[9] Belinson J.L., Wu R., Belinson S.E., Qu X., Yang B., Du H. et al.: “A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid captures 2 and Cervista from the SHENCCAST II Study”. Am. J. Clin. Pathol., 2011, 135, 790.

[10] Kedzia W., Jozefiak A., Pruski D., Rokita W., Marek S.: “Human papilloma virus genotyping in women with CIN 1”. Ginekol. Pol., 2010, 81, 664.

[11] Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M.: “Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication”. Int. J. Cancer, 2011, 128, 927.

[12] Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., et al.: “Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer”. Vaccine, 2012, 30, F88.

[13] Sun Z.R., Ji Y.H., Zhou W.Q., Zhang S.L., Jiang W.G., Ruan Q.: “Characteristics of HPV prevalence among women in Liaoning Province, China”. Int. J. Gynecol. Obstet., 2010, 109, 105.

[14] Clifford G.M., Smith J.S., Plummer M., Muñoz N., Franceschi S.: “Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis”. Br. J. Cancer, 2003, 88, 63.

[15] Shi J.F., Qiao Y.L., Smith J.S., Dondog B., Bao Y.P., Dai M., et al.: “Epidemiology and prevention of human papillomavirus andcervical cancer in China and Mongolia”. Vaccine, 2008, 26, M53.

[16] Liu S.S., Chan K.Y., Leung R.C., Chan K.K., Tam K.F., Luk M.H. et al.: “Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women–a population-based study”.PloS one, 2011, 6, e19244.

[17] Husaiyin S., Niyazi M., Wang L.H., Wang J.J., Wang J.B., Simayi A., et al.: “HPV infection among Uygur women in a rural area of Hetian Prefecture, Xinjiang UygurAutonomous Region, China”. J. Biomed. Environ. Sci., 2013, 26, 934.

[18] Zhao J., Zhang X., Ma J., Liu G., Yao D., Zhang W. et al.: “Clinical performance characteristics of the cervista HPV HR test kit in cervical cancer screening in china”. Low. Genit. Tract Dis., 2012, 16, 358.

[19] Min K.J., So K.A., Lee J., Hong H.R., Hong J.H., Lee J.K., et al.: “Comparison of the Seplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media”. J. Gynecol. Oncol., 2012, 23, 5.

[20] Wiwanitkit V.: “Cervista HPV HR test kit in cervical cancer screening”. J. Low. Genit. Tract Dis., 2013, 17, 99.

[21] Du Chateau B.K., Schroeder E.R., Munson E.: “Clinical laboratory experience with cervista HPV HR as a function of cytological classification:comparison with retrospective digene HC2 hig -risk HPV DNA test data”. Clin. Microbiol., 2013, 51, 1057.

[22] Kjær S.K., Frederiksen K., Munk C., Iftner T.: “Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence”. Natl. Cancer Inst., 2010, 102, 1478.

[23] Solomon D., Schiffman M., Tarone R.: “Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial”. J. Natl. Cancer Inst., 2001, 93, 293.

[24] Einstein M.H., Martens M.G., Garcia F.A., Ferris D.G., Mitchell A.L., Day S.P. et al.: “Clinical validation of the Cervista HPV HR and l6/18 genotyping tests for use in women with ASC- US cytology”.J. Gynecol. Oncol., 2010, 118, 116.